[Blog] Who's funding stem cell research?
By Jim Fossett,
Bioethics.net
| 08. 14. 2007
We've been arguing for a long time here that states have been spending more on human embryonic stem cell(hESC) research than the feds, and now we have some numbers to back it up. In a piece just posted on the Rockefeller Institute of Government website, we try to tote up who's spending how much on stem cell research in general and hESC in particular. While we can't be nearly as precise as we'd like, several things are clear..
+ The feds aren't spending much at all. Total stem cell allocations via NIH has been roughly flat at $640 million annually for the last couple of years. Only about six percent of that, or roughly $40 million annually, goes for hESC research.
+ States are spending more than the feds on hESC. California by itself has already obligated more than $200 million to hESC research, making it the largest hESC funder in the world. The California Institute of Regenerative Medicine (CIRM), the state agency which manages the stem cell program, is spending more than five times what NIH is spending...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Patrick Foong, BioNews | 11.03.2025
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...